Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways

Approval of checkpoint inhibitors for treatment of metastatic triple negative breast cancer (mTNBC) has opened the door for the use of immunotherapies against this disease. However, not all patients with mTNBC respond to current immunotherapy approaches such as checkpoint inhibitors. Recent evidence...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Michelle M. Williams, Sabrina A. Hafeez, Jessica L. Christenson, Kathleen I. O’Neill, Nia G. Hammond, Jennifer K. Richer
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
R
Acceso en línea:https://doaj.org/article/e2edb5704120464694919c5e63ee7665
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares